Literature DB >> 2861774

Memory function and brain biochemistry in normal aging and in senile dementia.

B Winblad, J Hardy, L Bäckman, L G Nilsson.   

Abstract

One might argue that the decrease in the number of brain cells as a function of age could be the source of the functional age deficits in memory performance. However, this possibility seems less likely since the actual loss of neurons up to advanced age is relatively small. There are no good estimates of the loss of synapses. Golgi staining of cortical neurons would indicate that there is a loss with higher age. So far, however, the most convincing data of marked loss with age appear at the biochemical level. Most human data fail to demonstrate a decrease in cholinergic and serotonergic activity as a function of normal aging, although there is a loss of corresponding receptors. In AD/SDAT, however, there is a marked damage to these systems. Conceivably, acetylcholine may be providing informational rather than tone setting or balancing influence on memory function. This may explain the failure of cholinomimetic drugs to improve memory in AD/SDAT due to their inability to supply the informational properties of normal neuronal transmission. The catecholamines, noradrenaline and dopamine are both lost in normal aging and to a much higher degree in AD/SDAT. Animal data show that noradrenaline deficiency results in scattered attention. Such a pattern might also exist in the intact aged and through guidance by means of instructions, contextual cues, and a richer TBR information, the elderly are being forced to attend. This may promote and supersede the normal functions of the noradrenaline system by directions from external rather than internal influences, conceivably by potentiating the remaining noradrenaline neurons. The cortical motor areas are relatively spared from neuro-degenerative changes in normal aging and in AD/SDAT and this might provide a neuroanatomical basis for the elderly's and mildly to moderately demented patients' success in memory performance when motor action is involved. The role of dopamine in motor function and its stability with age in hippocampus may also provide a neurochemical basis for the preservation of memory when the subjects are allowed to act physically during encoding.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2861774     DOI: 10.1111/j.1749-6632.1985.tb37595.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  9 in total

Review 1.  Dopaminergic insufficiency reflecting cerebral ageing: value of a dopaminergic agonist, piribedil.

Authors:  H Ollat
Journal:  J Neurol       Date:  1992       Impact factor: 4.849

2.  Effects of aging and levodopa on the laryngeal adductor reflex in rats.

Authors:  Xin Feng; Zengrui Xu; Susan G Butler; Iris Leng; Tan Zhang; Stephen B Kritchevsky
Journal:  Exp Gerontol       Date:  2012-07-21       Impact factor: 4.032

3.  Brain monoaminergic and neuropeptidergic variations in human aging.

Authors:  B Arranz; K Blennow; R Ekman; A Eriksson; J E Månsson; J Marcusson
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  Modulation of the influences of cortical input on hippocampal neurons by cholinergic substances.

Authors:  O S Vinogradova; E S Brazhnik; V S Stafekhina; V F Kichigina
Journal:  Neurosci Behav Physiol       Date:  1996 Jan-Feb

5.  Modulation of the reaction of hippocampal neurons to sensory stimuli by cholinergic substances.

Authors:  O S Vinogradova; E S Brazhnik; V F Kichigina; V S Stafekhina
Journal:  Neurosci Behav Physiol       Date:  1996 Mar-Apr

6.  Comparative effects of alpha-2 receptor agents and THA on the performance of adult and aged rats in the delayed non-matching to position task.

Authors:  J Sirviö; M Harju; P Riekkinen; A Haapalinna; P J Riekkinen
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

7.  Bupropion and Citalopram in the APP23 Mouse Model of Alzheimer's Disease: A Study in a Dry-Land Maze.

Authors:  Katharina L Neumeister; Matthias W Riepe
Journal:  Int J Alzheimers Dis       Date:  2012-09-29

8.  The dopamine β-hydroxylase -1021C/T polymorphism is associated with the risk of Alzheimer's disease in the Epistasis Project.

Authors:  Onofre Combarros; Donald R Warden; Naomi Hammond; Mario Cortina-Borja; Olivia Belbin; Michael G Lehmann; Gordon K Wilcock; Kristelle Brown; Patrick G Kehoe; Rachel Barber; Eliecer Coto; Victoria Alvarez; Panos Deloukas; Rhian Gwilliam; Reinhard Heun; Heike Kölsch; Ignacio Mateo; Abderrahim Oulhaj; Alejandro Arias-Vásquez; Maaike Schuur; Yurii S Aulchenko; M Arfan Ikram; Monique M Breteler; Cornelia M van Duijn; Kevin Morgan; A David Smith; Donald J Lehmann
Journal:  BMC Med Genet       Date:  2010-11-11       Impact factor: 2.103

9.  A Novel and Selective Dopamine Transporter Inhibitor, (S)-MK-26, Promotes Hippocampal Synaptic Plasticity and Restores Effort-Related Motivational Dysfunctions.

Authors:  Shima Kouhnavardi; Alev Ecevitoglu; Vladimir Dragačević; Fabrizio Sanna; Edgar Arias-Sandoval; Predrag Kalaba; Michael Kirchhofer; Jana Lubec; Marco Niello; Marion Holy; Martin Zehl; Matthias Pillwein; Judith Wackerlig; Rita Murau; Andrea Mohrmann; Kathryn R Beard; Harald H Sitte; Ernst Urban; Claudia Sagheddu; Marco Pistis; Roberto Plasenzotti; John D Salamone; Thierry Langer; Gert Lubec; Francisco J Monje
Journal:  Biomolecules       Date:  2022-06-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.